Literature DB >> 17561823

Chronic bupropion attenuated the anhedonic component of nicotine withdrawal in rats via inhibition of dopamine reuptake in the nucleus accumbens shell.

Neil E Paterson1, David J Balfour, Athina Markou.   

Abstract

Bupropion, a dopamine reuptake inhibitor, is an effective therapy for smoking cessation, but the behavioral and neurochemical mechanisms mediating its antismoking properties are relatively unknown. To explore the hypothesis that bupropion ameliorates nicotine withdrawal partly by a dopamine-dependent mechanism, we investigated the effects of chronic bupropion on potassium-stimulated dopamine overflow in the nucleus accumbens shell in nicotine-withdrawing rats. We also assessed the effects of chronic bupropion on behavioral aspects of nicotine withdrawal measured by elevations in brain reward thresholds and somatic signs of withdrawal. Rats were treated with nicotine or saline for 7 days and then coadministration of bupropion or saline was initiated. After 14 days of coadministration of bupropion/saline and nicotine/saline, nicotine/saline administration was terminated, whereas bupropion/saline administration continued. These conditions mimic bupropion administration in human smokers. Cessation of nicotine administration in non-bupropion-treated rats elevated reward thresholds reflecting a reward deficit, increased somatic signs and diminished potassium-evoked dopamine overflow in the nucleus accumbens shell. Chronic bupropion lowered reward thresholds and increased potassium-evoked dopamine release regardless of previous nicotine exposure, possibly by inhibition of dopamine reuptake, and thus attenuated the anhedonic and neurochemical effects of nicotine withdrawal. Chronic bupropion blocked withdrawal-associated increased somatic signs. Finally, acute experimenter-administered nicotine enhanced brain reward function equally in all groups, indicating that bupropion does not alter the reward-facilitating effects of experimenter-administered nicotine. In conclusion, the bupropion-induced increase in extracellular dopamine in the nucleus accumbens shell may ameliorate the anhedonia associated with nicotine withdrawal, which in turn may facilitate smoking cessation.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17561823     DOI: 10.1111/j.1460-9568.2007.05546.x

Source DB:  PubMed          Journal:  Eur J Neurosci        ISSN: 0953-816X            Impact factor:   3.386


  32 in total

1.  Increased dopamine receptor activity in the nucleus accumbens shell ameliorates anxiety during drug withdrawal.

Authors:  Anna K Radke; Jonathan C Gewirtz
Journal:  Neuropsychopharmacology       Date:  2012-06-13       Impact factor: 7.853

Review 2.  Reconsidering anhedonia in depression: lessons from translational neuroscience.

Authors:  Michael T Treadway; David H Zald
Journal:  Neurosci Biobehav Rev       Date:  2010-07-11       Impact factor: 8.989

3.  Performance and thermoregulatory effects of chronic bupropion administration in the heat.

Authors:  Bart Roelands; Hiroshi Hasegawa; Philip Watson; Maria Francesca Piacentini; Luk Buyse; Guy De Schutter; Romain Meeusen
Journal:  Eur J Appl Physiol       Date:  2008-11-12       Impact factor: 3.078

4.  Effects of smoking abstinence, smoking cues and nicotine replacement in smokers with schizophrenia and controls.

Authors:  Jennifer W Tidey; Damaris J Rohsenow; Gary B Kaplan; Robert M Swift; Amy B Adolfo
Journal:  Nicotine Tob Res       Date:  2008-06       Impact factor: 4.244

5.  Both GABA(B) receptor activation and blockade exacerbated anhedonic aspects of nicotine withdrawal in rats.

Authors:  Styliani Vlachou; Neil E Paterson; Sebastien Guery; Klemens Kaupmann; Wolfgang Froestl; Deboshri Banerjee; M G Finn; Athina Markou
Journal:  Eur J Pharmacol       Date:  2011-01-22       Impact factor: 4.432

Review 6.  Negative affective states and cognitive impairments in nicotine dependence.

Authors:  F Scott Hall; Andre Der-Avakian; Thomas J Gould; Athina Markou; Mohammed Shoaib; Jared W Young
Journal:  Neurosci Biobehav Rev       Date:  2015-06-06       Impact factor: 8.989

Review 7.  Don't stress about CRF: assessing the translational failures of CRF1antagonists.

Authors:  Samantha R Spierling; Eric P Zorrilla
Journal:  Psychopharmacology (Berl)       Date:  2017-03-07       Impact factor: 4.530

8.  Combination treatment with varenicline and bupropion in an adaptive smoking cessation paradigm.

Authors:  Jed E Rose; Frédérique M Behm
Journal:  Am J Psychiatry       Date:  2014-11-01       Impact factor: 18.112

9.  Differential effects of withdrawal from intermittent and continuous nicotine exposure on reward deficit and somatic aspects of nicotine withdrawal and expression of α4β2* nAChRs in Wistar male rats.

Authors:  Svetlana Semenova; Xinchun Jin; Tristan D McClure-Begley; Matthew Philip Tadman; Michael J Marks; Athina Markou
Journal:  Pharmacol Biochem Behav       Date:  2018-06-14       Impact factor: 3.533

10.  Acute effect of the anti-addiction drug bupropion on extracellular dopamine concentrations in the human striatum: an [11C]raclopride PET study.

Authors:  Alice Egerton; John P Shotbolt; Paul R A Stokes; Ella Hirani; Rabia Ahmad; Julia M Lappin; Suzanne J Reeves; Mitul A Mehta; Oliver D Howes; Paul M Grasby
Journal:  Neuroimage       Date:  2009-12-05       Impact factor: 6.556

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.